In the grand scheme of things, an unforgiving pancreas cancer could kill a person in a few months, and managing some ...

Shame, fueled by stigma, can deter care for HIV patients; recognizing it and responding compassionately can reduce harm, ...

Demand for care keeps rising, but the workforce is not keeping up. According to Experian Health's 2026 State of Patient ...

In the final episode, ‘The Future Landscape: Topical vs. Systemic JAK Inhibitors in Vitiligo ,’ the panelists explored the ...

Results from a study on an investigational combination treatment for patients with advanced KRAS G12C+ non-small cell lung ...

Divarasib plus pembrolizumab shows strong responses in patients with advanced KRAS G12C+ non-small cell lung cancer, ...

The results from Krascendo 170 support further development of divarasib plus pembrolizumab as a chemotherapy-free first-line ...

Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone ...

Phase 3 ROADS enrolled 204 patients across 32 centers (2021–2025) with 2–7 cm brain metastases, comparing tile-based intraoperative radiation versus external stereotactic radiation. Surgical bed ...

Daraxonrasib, a first-in-class multi-RAS inhibitor, doubles survival in metastatic pancreatic cancer and hints at broader, mutation-agnostic impact. When RASolute 302 data were presented at the ...

FDA approval covers ready-to-use romidepsin for previously treated CTCL, and CGT designation provides Amneal 180 days of market exclusivity. CTCL commonly manifests as red, scaly skin patches in men ...

Please check back later for more content.